CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
anidulafungindrug
Likely dose
anidulafungin 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01202253
NCT01202253N/ACompleted

A Study To Describe The Early Clinical Experience With Anidulafungin In Patients With Liver Disease At King's College Hospital NHS Trust, London

Pfizer·observational·Posted Sep 15, 2010·Updated Apr 16, 2014

In Brief

An observational study evaluating anidulafungin for Candidiasis. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCandidiasis
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 15, 2010
Enrollment StartFeb 1, 2011
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.8 years ago

Interventions

anidulafungindrug

A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.